A composition for the treatment of cancerous cells, said composition including a combination of at least one Tumor Necrosis Factor receptor (TNFR) agonist and at least one thioredoxin inhibitor. This combinatorial approach involves direct inhibition of the Thioredoxin molecule (and not the enzyme of Trx reductase).